Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy, Believes ALNY Has More Overlooked Catalysts than Most Peers
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), following recent discussions with the company's CEO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
